Tools to help radiology residents get information on fellowships.
While the timeline for fellowship applications is set by the institution, there are general guidelines. Some applications are accepted as early as April of the second year, but more commonly starting in June or July. The process is complete by the end of the residents’ third year.
RSNA Fellowship Connect is a good place to start and offers a comprehensive program database.
Here is information on a few of the most popular subspecialties:
MSK: MSK fellowship applications are usually due between June and August, at the end of yoursecond year to beginning of third year (though some programs accept applications starting in May, and others accept them through September). The Society of Skeletal Radiology gives a full list of fellowships with information and website links.
Neuro and IR: These subspecialties use the match program. The 2015 application dates for the match program for fellowships starting in 2016 were: March 4 for match opening, with rankings due June 3, and a June 17 match date. Application and interview dates are set by the individual programs.
Interview dates for 2016 fellowship applicants in interventional radiology were January 15 - April 14, 2015.
Neuroradiology interview dates for 2016 fellowship applicants were October 1, 2014 - February 28, 2015.
Breast imaging: Breast imaging fellowship programs tend to request applications June through August between the second and third year of residency, though specific dates depend on the institution. Interviews tend to be in the fall. The Society of Breast Imaging lists all breast fellowships on their site.
Find advice on how to choose a fellowship here.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.